Subscribe To
medicinova’s collaborator initiates clinical development of a gene therapy product for the treatment of phenylketonuria
LA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
October 27, 2023, 5:00 am
medicinova receives a notice of allowance for a new patent covering the combination of mn-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (als) in canada
LA JOLLA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
October 10, 2023, 11:00 pm
medicinova announces results of studies under barda contract to develop mn 166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung injury
LA JOLLA, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company tra...
September 27, 2023, 11:00 pm
medicinova announces abstract regarding mn-166 (ibudilast) in glioblastoma accepted for presentation at the annual meeting of the society for neuro-oncology
LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
August 17, 2023, 11:00 pm
medicinova receives a notice of intention to grant for a new patent covering mn-166 (ibudilast) for the treatment of macular injury in europe
LA JOLLA, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
August 16, 2023, 11:00 pm
medicinova stock up on european patent award
medicinova Inc (NASDAQ:MNOV) stock started Wednesday on the front foot boosted by a patent award in Eur...
August 16, 2023, 10:15 am
medicinova receives a new patent covering mn-001 for the treatment of scleroderma and systemic sclerosis in europe
LA JOLLA, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
August 15, 2023, 11:00 pm
medicinova receives a notice of intention to grant for a new patent covering mn-001 and mn-002 for the treatment of advanced nash in europe
LA JOLLA, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
August 14, 2023, 11:00 pm
medicinova announces presentation of results from the phase 2b trial of mn-166 (ibudilast) in alcohol use disorder at the 46th annual research society on alcohol (rsa) scientific meeting
LA JOLLA, Calif., June 29, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
June 29, 2023, 10:00 am
medicinova receives a notice of intention to grant for a new patent covering mn-166 (ibudilast) for patients with microorganism infection in europe
LA JOLLA, Calif., May 14, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trade...
May 14, 2023, 11:00 pm
medicinova receives a notice of allowance for a new patent covering mn-001 for the treatment of advanced nash in canada
LA JOLLA, Calif., April 30, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company tra...
April 30, 2023, 11:00 pm
medicinova announces additional extension of barda contract to develop mn-166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung injury
LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company tra...
March 9, 2023, 11:00 pm
medicinova receives a notice of allowance for a new patent covering mn-001 and mn-002 for the treatment of scleroderma and systemic sclerosis in canada
LA JOLLA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
January 11, 2023, 3:00 am
medicinova receives a notice of allowance for a new patent covering mn-001 and mn-002 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia in brazil
LA JOLLA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
January 10, 2023, 3:00 am
medicinova announces additional positive results regarding the effects of mn-001 (tipelukast) on serum lipid panel in type 2 diabetes and nafld patients presented at idf 2022 congress, the annual meet
LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
December 6, 2022, 11:00 pm
medicinova announces additional positive results regarding the effects of mn-001 (tipelukast) on serum lipid panel in type 2 diabetes and nafld patients presented at idf 2022 congress, the annual meet
LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
December 6, 2022, 11:00 pm
medicinova announces positive results from secondary analysis of phase 2 trial of mn-166 (ibudilast) published in the american journal of drug and alcohol abuse
LA JOLLA, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) — medicinova, Inc., a biopharmaceutical company trad...
December 5, 2022, 11:00 pm
medicinova posts promising data from covid-19 treatment candidate
medicinova Inc (NASDAQ: MNOV) says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 pa...
June 8, 2022, 9:15 am